According to ABTA statistics, brain and CNS tumors are the third most common type of cancer among people under the age of 40. The market is expected to grow as the use of gamma knife therapy in neurological treatment grows due to its advantages over traditional operations. It offers higher safety, less damage to surrounding tissues, and micro accuracy while treating the target cells in the brain because it is a non-invasive process.
The market is likely to be driven by increased usage of these instruments in surgery centers as a result of the rising prevalence of neurological illnesses and the growing desire for minimally invasive treatments. Demand for the recently developed Leksell Gamma Knife Icon is rapidly expanding, and there is a greater need for this technology to be upgraded. Elekta Instrument, AB, for example, improved existing gamma knife models U, B, C, 4C, and Perfexion to Leksell Gamma Knife Icon in 2015. As a result, constant technological advancement in gamma knife is one of the major factor that can be attributed to its widespread popularity. The high use of these devices in surgical centers is due to the adoption of integrated imaging and software, enhanced workflow, and an increase in clinical applications.
Over the projected period, the ocular illness segment is expected to grow at a profitable rate of around 12.1%. Uveal melanoma, advanced glaucoma, eye metastases, age-related macular degeneration, angioreticuloma, cognitive discomfort, and pseudotumor cerebri are among the ocular indications for which gamma knife therapy is utilized. It lowers intraocular pressure and has a short delay in comparison to other treatments. As a result, expanded applications of this therapy to treat a variety of ocular diseases are predicted to drive up demand.
North America leads the market, followed by Europe, the other developed area. The US controls a significant portion of the worldwide market. The American Cancer Society estimates that 1,685,225 new cancer cases were detected in 2018. The rise of the gamma knife technology market in North America was affected greatly by advanced technologies, high awareness levels, and high purchasing power. However, the same issue of affordability has stifled growth in underdeveloped markets.
Despite a huge decline in the sales of products during the initial phase of pandemic spread and lockdown restrictions all over the region, the market is observed to pick up a quick pace for registering a CAGR of almost more than 3.7 %, during the tenure of 2021 – 2027.
The report published by Maximize encompasses the market dynamics, which could affect the market growth of the Gamma Knife Market in the region, the Value – Chain Analysis, and the PORTER’s analysis for the Gamma Knife Market at a global level. The study is associated based on major segments and further into sub-segments, Indication (ChemoIndication, Hormonal Indication, ImmunoIndication, RadioIndication) to forecast the market size by value; also includes the analysis of past market dynamics from 2016 – 2019, considering 2020 as the base year.
Lastly, the market research report provides a regional comparison and a complete country-level analysis for the Technology trends, along with the major key players- Elekta AB, Varian Medical Systems, Cyber Medical Corp., ET Medical Group, GE Healthcare, Masep Infini Global Inc. Huiheng Medical, Inc, Nordion Inc., American Shared Hospital Services, Austromar S.R.O.
Combimar & Agemar SpA, Shine International Transportation, Transglory S.A., New Lines CO, Ltd, Pacific Star International. China, SHANGHAI SNWI MEDICAL CO., LTD., Shenzhen Tengfei Yu Technology Co., Ltd., Shanghai Even Medical Instruments Co., Ltd.
You can browse the market data Tables and Figures spread through a comprehensive research report and in-depth TOC on the “Global Gamma Knife Market.”
https://www.maximizemarketresearch.com/market-report/global-gamma-knife-market/120871/
Contact:
MAXIMIZE MARKET RESEARCH PVT. LTD.
Omkar Heights,
ManikBaug, Vadgaon Bk,
Sinhagad Road, Pune – 411051,
Maharashtra, India.
+91 9607195908